Beyfortus
My Prescription
Payment
Select pharmacy
$621.24
Print or send this coupon to your phone
AlbertsonsPowered byAbout Beyfortus
Drug Details
Nirsevimab, marketed as Beyfortus, is an injection used to prevent serious lung infections caused by the respiratory syncytial virus (RSV) in infants and young children up to 24 months old. This drug is a monoclonal antibody, specifically designed to provide short-term protection by preventing the virus from entering cells and spreading. It is ideally administered during or at the start of the RSV season to offer optimal defense against the virus. Approved by the FDA in July 2023, Beyfortus is recognized for its effectiveness and minimal side effects, making it a reliable option for safeguarding children at risk of severe RSV illness.
Price history for Beyfortus
1 Syringe, 0.5ML of 50MG/0.5ML
Average retail price for Beyfortus
Average SaveHealth price for Beyfortus
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Beyfortus dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 0.5ML of 50MG/0.5ML | 1 Syringe | $622.10 | $622.10 |
| 0.5ML of 50MG/0.5ML | 2 Syringes | $1,229.19 | $614.60 |
| 0.5ML of 50MG/0.5ML | 3 Syringes | $1,832.13 | $610.71 |
| 1ML of 100MG/ML | 1 Syringe | $622.10 | $622.10 |
| 1ML of 100MG/ML | 2 Syringes | $1,229.19 | $614.60 |
| 1ML of 100MG/ML | 3 Syringes | $1,832.13 | $610.71 |
Beyfortus FAQs
Beyfortus is used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and young children.
Beyfortus, also known as nirsevimab, is considered safe for use in its intended population. It has undergone clinical trials to evaluate its safety and efficacy. As with any medication, there may be potential side effects, and it is important for healthcare providers to assess the benefits and risks for each individual patient. Common side effects are generally mild and may include reactions at the injection site. It is always recommended to discuss any concerns with a healthcare provider.
As of the latest information available, Beyfortus (nirsevimab) has not been approved by the U.S. Food and Drug Administration (FDA). It is important to check the most current sources or FDA announcements for any updates regarding its approval status.
Beyfortus is not a vaccine; it is a monoclonal antibody used for the prevention of respiratory syncytial virus (RSV) in infants and young children.
Yes, Beyfortus is a monoclonal antibody.